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IRAS number  248606 
Study type & design A multi-centre, four-arm, controlled, prospective randomised 
trial of the effect of a patient’s position during GON block 
intervention (ie non-medicinal, non-device)  
Patient population Adults with mental capacity and without any significant 
comorbidities who are diagnosed with a headache disorder 
(migraine [episodic or chronic], occipital neuralgia, cluster 
headache, trigeminal autonomic cephalgia [TAC], other) 
unresponsive or poorly responsive to pharmacological 
treatments. 
 
Primary objective 
 
Any difference in headache RELIEF score post-GON block 
intervention, as recorded by patients at 90 days post-
intervention. 
 
Secondary objectives 
 
Any difference in headache RELIEF score post-GON block 
intervention, as recorded by patients at 30 days post-
intervention. 
 
Any difference in number of headache-free days post-GON block 
intervention (as recorded by patients using the Curelator 
headache app and retrospective recall) at 30 and 90 days post-
GON block. 
 
Any change in headache severity, related symptoms, frequency 
and duration – baseline versus follow-up at 30 days and 90 days  
 
Impact of headache disorder on quality of life as measured by 
validated HIT6, MIDAS and MSQ questionnaires at 30 and 90 
days 
 
Any change in prophylactic and/or rescue medication use, and 
its potential economic impact. 
 
Analysis of variables that may be associated with favourable 
outcomes after GON block through multi-regression analysis 
 
Safety of both patient positioning approaches post-GON block 
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Primary headache disorders, including migraine, cluster headache, and occipital neuralgia, 
are some of the most debilitating conditions that impact negatively on patients themselves 
and the wider economy. A subset of patients does not respond to currently available 
prophylaxis and rescue medication. Nerve block medication treatment is offered to these 
treatment-resistant patients. Greater occipital nerve block (GON block) is an established 
nerve block procedure that has a favourable safety profile and is cost-effective – the active 
ingredients used are a mix of local anaesthetic agent and steroid. The exact effectiveness 
and the optimal method for delivering GON block is to be finalised due to a relative lack of 
evidence from gold-standard randomised controlled trials and variety in the applied GON 
block procedure. Initial pilot data on GON block patients, and related evidence from use of 
anaesthetics in dentistry, suggests that lying a patient down for ten minutes after the 
procedure enhances the effectiveness of the GON block and thereby leads to an increase in 
the achieved headache-free period. This present study seeks to use a prospective, 
randomised, multi-centre approach to determine whether the patient’s position straight 
after injection of the GON block medicine influences the patient-reported outcomes 
regarding headache symptoms afterwards. A headache-reporting App called Curelator, used 
by participating patients during the trial period, will allow prospective recording of 
headaches which may reduce the bias observed with retrospective patient recall of 
headache episodes. 
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Primary headache disorders including migraine, occipital neuralgia, and cluster headache 
have a high prevalence. In terms of years of life lost to disability, headache disorders rank 
third among worldwide causes of disability (Steiner et al, 2015). When considered 
separately, worldwide migraine has a one-year prevalence of over 10%, with a higher 
prevalence in developed countries (Robins and Lipton, 2010).  
Oral pharmacological treatment of primary headache disorders is the mainstay of patient 
management, both in terms of prophylaxis and treatment of headache episodes. However, 
interventional procedures such as peripheral nerve blocks (PNBs) and trigger point 
injections (TPIs) have long been used in the treatment of various headache disorders (Evans 
and Yannakakis, 2001). Nerve blocks by means of Botulinum toxin type A or anaesthetic 
agents such as lidocaine or bupivacaine are established treatment modalities (Terzi et al, 
2002; Levin, 2010; Escher et al, 2017). Although various nerves – such as lesser occipital, 
auriculotemporal, supratrochlear and supraorbital nerves, sphenopalatine ganglion, cervical 
spinal roots, and facet joints of the upper cervical spine - a common target is the greater 
occipital nerve (GON). There is not a widely accepted agreement among headache 
specialists with regards to the optimal GON block methodology, such as used injecting 
technique, type and doses of the local anaesthetics and corticosteroids (Tobin and Flitman, 
2009). For example, the role of corticosteroids in this setting is still debated (Caputi and 
Firetto, 1997; Ashkenazi and Young, 2005).  
The specific conditions treated with GON block vary and include both primary (e.g. migraine, 
cluster headache) and secondary (e.g. cervicogenic) headache disorders (Ashkezani et al, 
2010). Despite favourable outcomes reported by many practitioners, there is still a relative 
lack of scientific evidence and data (Young et al, 2008; Tobin and Flitman, 2009). Most 
studies are small sample size, heterogeneous sample groups, limited by retrospective design 
and lack of control arm. Moreover methodology used varies greatly, making generalisation 
and comparison of the results difficult. Sitting up following a GON block procedure is 
currently considered the standard way of managing a patient, however studies do not 
actually specify this within their methodology. This prospective randomised controlled 
multi-centre trial evaluates whether the patient’s positioning following GON block affects 
the efficacy of the treatment in terms of achieving a headache-free period and overall 
degree of headache relief. 
 #	$%!"%& &'"( !"
The rationale for using GON block as a treatment for headache comes from the proximity of 
sensory neurons in the upper cervical spinal cord to trigeminal nucleus caudalis (TNC) 
neurons and the convergence of sensory input to TNC neurons from both cervical and 
trigeminal fibres. The evidence for this comes from several studies. In an animal study, 
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stimulation of the GON was shown to increase metabolic activity in the TNC, as well as in 
the upper cervical dorsal horn (Goadsby et al, 1997). The same neural sites are activated 
after mechanical or electrical stimulation of trigeminal nerve innervated structures, such as 
the superior sagittal sinus (Goadsby and Zagami, 1991). These observations suggest that a 
convergence of sensory input from cervical and trigeminal afferents occurs at the level of 
the second order afferent neurons in the TNC. In further support of this hypothesis, Bartsch 
and Goadsby (2002) demonstrated in a rat model of cranial nociception that dorsal horn 
neurons at the C2 level respond to stimulation of both the dura and the GON. Moreover, 
stimulation of the GON facilitates C2 neuronal response to dura mater stimulation. In 
accordance with these data, it has been shown in humans that GON block may result in 
alleviation of pain even outside of the skin territory supplied by the nerve (Peres et al, 
2002).  
There is no standard protocol for Greater Occipital Nerve block procedure. The usual 
procedure – used in Cumbria Partnership NHS FT and in this present study - consists of 
inserting a 23-gauge needle into at the medial third of the distance between the occipital 
protuberance and the mastoid process (Figure 1) and infiltrating the nerve with a local 
anaesthetic (2% Lidocaine) with a corticosteroid (Depo-Medrone 80 mg). GON block is an 
easy-to-perform and relatively economical procedure with a favourable safety profile that 
can be performed in an outpatient clinic setting. 
 
Figure 1: Anatomy of the Occipital nerves 
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There is a wide variety in response rates to GON block. The published response interval lies 
between a few days and 3 months. Afridi reported that in migraine patients yield a 
complete or partial response that lasted - for the partial response - a median of 30 days. For 
cluster headache, 13 of 22 injections yielded a complete or partial response lasting for a 
median of 21 days for the partial response (Afridi et al, 2006). Tobin identified 21 articles 
researching benefit of GON block and found that the duration of reported benefit was 
between 1-4 weeks in most studies.  The reported benefit did not exceed median of 32 days 
after a single treatment in any of the studies (Tobin and Flitman, 2009).  
At a local level, a pilot study (submitted for publication) has revealed that for those patients 
who follow the standard protocol for GON block, ie sitting down after the procedure, the 
median achieved headache-free period is 7 days. The headache-free period is 56 day for 
those patients who lie down (supine) for 10 minutes following GON block (see also Figure 2). 
In this study, a mix of primary headache disorders was included in the respective cohorts.   
Table 1 shows that the diagnosis does not affect the headache-free period achieved. Only 
chronicity of the condition (negatively) and the patient’s position (positively for supine) 
were significantly associated with the achieved headache-free period. 
 
Figure 2: Headache-free days after GON block for Cumbrian patients, stratified by RELIEF 
score 
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Table 1: backward multiple linear regression analysis: headache-free period (days) as 
dependent 
Variable Beta p-value  
Sex -0.089 0.43 
Patient age (yrs) -0.020 0.86 
Chronicity of condition -0.21 0.12 
History of GON block 0.069 0.54 
Main diagnosis -0.043 0.74 
Baseline headache severity 0.033 0.77 
Baseline headache duration -0.054 0.65 
Baseline headache frequency 0.11 0.34 
Patient position post-GON 0.23 0.041* 
Most significant variables 
Chronicity of condition -0.24 0.024* 
Patient in supine position post-GON 0.25 0.018* 
*statistically significant correlation (p-value < 0.05) 
 
 
 " (')*!'&("(
 
We hypothesise that a patient placed in a horizontal (supine) position for 10 minutes 
directly after the GON block will prolong duration of the procedure’s benefit from the 
procedure compared to a patient seated up (sitting). GON block has a favourable safety 
profile and, once a clinician is trained, is an easy-to-perform procedure that can be 
performed in an outpatient clinic setting. Retaining the patient in a horizontal position for 
10 minutes after the procedure does not pose a significant change to the practice, since 
patients will usually recover for a few minutes anyway whilst seated in the clinic room. This 
study evaluates whether the patient’s positioning following GON block affects the efficacy 
of the treatment in terms of achieving a headache-free period and overall degree of 
headache relief. 
 
The null hypothesis is that the supine position is no different from the sitting position in 
terms of the achieved headache-relief following GON block. Using the RELIEF scale, non-
responders are those classed as ‘worsening of symptoms’, ‘no relief’, or ‘slight relief’. 
Responders will be those who indicate at follow-up that GON block gave them ‘substantial’ 
or ‘complete’ relief. 
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All participants will be given single treatment unilateral or bilateral GON block, inserting a 
22-23 gauge needle, using dose of Lidocaine 2% (20mg) with Depo-Medrone (80mg) in 2 ml 
vial, injected close to GON output (1/3 of distance between external protuberance and 
mastoid process).  
 
The intervention is as follows: directly following conclusion of the GON block procedure the 
patient will either 
A. Remain seated vertical (sitting)   
B. Lie horizontally in a supine position for 10 minutes (with head rested on pillow at 
appr 30 degree angle, see Figure 2), measured with stopwatch. 
 
Figure 3: patient position options (determined by randomisation) following GON block 
 
 
 
 
 
 
 
 
 
 &"%&/"&(&"!'&(!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The Curelator App will be used as a tool to record Patient-Related Outcome Measures 
(PROMs). Curelator (https://curelator.com/) was initially designed to identify triggers and 
protectors of migraine attacks. On a daily basis, headache patients can record if they have 
any headache episodes and if there were any factors that may contribute to said episode, 
such as change in weather, menstrual cycle, exercise, sleep quality etc. For this present 
study, the trigger/protector element will not be used.  
Curelator will be used primarily to allow participants to record : 
- Headache(-free) days.  
A (sitting) 
B (supine) 
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- Severity of headache episodes 
- Symptoms related to headache episodes. 
If they do have a headache, Curelator will be used prospectively to record the headache 
symptoms, including severity and length of the episode. To date, virtually all trials for 
headache treatments have used a paper diary. The paper approach is prone to bias, non-
compliance and reliance on patient recall. Therefore, the use of Curelator is a novel 
approach to recording headache frequency and characteristics. 
The user data for all participants will be available to the research team and neurologists via 
a Curelator dashboard. This will allow interpretation of the data for individual and collective 
patients. Furthermore, it can be used during the baseline period to ensure that the 
participant is compliant and sufficient data is collated prior to GON block. This is essential to 
allow comparison of headache symptoms pre- and post-GON block. Curelator complies with 
applicable UK data protection laws and regulation. 
 ("&%!&'&
 
Patients will record their headache frequency and intensity, in addition to other symptoms 
using Curelator HeadacheTM.  
 
Curelator Inc. (Cambridge USA) has developed a proprietary, non-pharmaceutical, digital 
platform, called Curelator Headache to collect daily data, identify potential trigger-attack 
associations and propose ‘tests’ of trigger modification. The underlying premise is that 
individual’s knowledge about their triggers and which, when modified or avoided, affect 
their condition, empowers the individual to better manage their lifestyle so as to improve 
their quality of life and reduce healthcare utilization. 
 
The Curelator approach requires high quality data from the individual, entered on a daily 
basis. Hence Curelator has developed a quick, easy to use, customized user interface and it 
is expected that with this a high degree of compliance with, and adherence to, many weeks 
of data entry can be achieved. Compliance is expected to be enhanced because the study is 
being offered by the individual’s healthcare provider. 
 
Curelator Headache currently consists of multiple, linked components: 
 
1. A website that informs visitors about Curelator Headache and how to sign up as a 
clinical trial subject or user. 
 
2. A Web based process to set up users with a username and secure password and a 
secure on-line registration process (termed ‘onboarding’) during which users are 
assessed regarding eligibility criteria, informed about the study, informed consent 
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can be obtained, and also demographic and relevant medical history data is 
collected. 
 
3. An app which runs on iPhones and iPads (compatible with iOS 9 and above), and 
other compatible smartphones/tablets (Android 4.1 and above). Using this, data are 
entered about headaches and about daily behaviours and exposure to possible 
migraine triggers, via a series of questions. Daily questions modules will be pre-
configured for this study, in agreement with the Chief Investigator.  
 
4. A secure database hosted in a HIPAA compliant datacenter which is maintained by a 
third-party company which specialises in data security and compliance (Armor 
Defense Inc., Richardson, Texas, USA) 
 
5. Data processing, statistical analysis and display algorithms located on multiple 
devices. These use anonymized data exported from Curelator’s secure database. 
Processed data are reimported to the database and re-linked to user identification 
so that processed information can be sent to the user. 
 
6. Users visualize their personal information via the app or secure web access. They can 
also print or export their data to other devices and email so that, for example, they 
can share it with their clinician. Users also grant permission to their clinicians to view 
data collected and run basic analysis on a secure web platform for physicians 
(Physician dashboard). 
 
7. A password-protected Physician dashboard through which the study doctor invites 
study subjects to use Curelator Headache as part of the study procedures.   Through 
the dashboard the doctor can monitor subject progress and review the subjects data 
and reports. 
 
The platform is illustrated below: 
 
Figure 4. Risk associated with Curelator Headache use 
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Use of Curelator Headache is not expected to pose any risk to patients. Proposed test 
interventions are limited to diet modification (for example avoidance of certain foods, 
alcohol, caffeine) and environmental factors (for example bright lights, loud noises) and 
guidance on lifestyle interventions (for example stress management and sleep hygiene) and 
implementing the protective factors. Curelator Headache may also identify signs in 
individuals that warn of an impending attack (for example neck pain, sensitivity of skin on 
the head): individuals may use this information to modify their behaviour to minimise the 
impact of an attack. 
 
Curelator Headache is NOT for the purpose of diagnosing headache type and will NOT 
propose any medication changes. 
 
Expected benefit is that Curelator Headache will identify one or more associations between 
potential triggers, warning signs, premonitory symptoms and/or protective factors and the 
occurrence of migraine attacks. At the end of the 90 day period Curelator will inform 
subjects about such associations, via their personal ‘trigger map’. Subjects will be able to 
produce succinct reports for their physician, which include visualisations of headache events 
over the study period, the trigger map and other data that may be clinical useful. These 
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outputs of Curelator will empower subjects to improve self-management and facilitate 
clinical management of their condition and aid physicians in treating their patients. 
 
Subjects who stop entering daily data will receive reminders. If no data are entered for 14 
days they will be sent a brief questionnaire asking if they no longer wish to enter data and, if 
so, the reasons for stopping use. No further follow up will be conducted. 
 
1 
	2
-
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The primary objective is to determine if there is any difference in headache RELIEF score 
post-GON block intervention, as recorded by patients at 90 days post-intervention. The first 
24 hours after GON block are excluded to avoid patients recording GON block procedure-
specific headache as a regular headache episode. 
 
 &)$3&!"/&
 
Any difference in headache RELIEF score post-GON block intervention, as recorded by 
patients at 30 days post-intervention. 
Any difference in number of headache-free days post-GON block intervention (as recorded 
by patients using the Curelator headache app and retrospective recall) at 30 days and 90 
days post-GON block compared to baseline 30 days data and between intervention arms. 
Any change in headache severity, related symptoms (such as aura, photophobia), frequency 
and duration – baseline 30 days versus follow-up 90 days and between intervention arms 
(recorded by patients using Curelator). 
Correlation for headache-free days comparing Curelator recordings vs patient retrospective 
recall.  
Any change in headache-related quality of life, as measured with patient-reported outcome 
measures (validated questionnaires HIT-6, MIDAS, MSQ). 
Any change in prophylactic and/or rescue medication use, and its potential economic 
impact. 
Analysis of variables that may be associated with favourable outcomes after GON block 
through multi-regression analysis 
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This concerns a multi-centre, controlled, prospective, randomised trial. The study will be 
carried out in the following NHS Trusts: 
- Cumbria Partnership NHS Foundation Trust, Neurology Department, Penrith, CA11 
8JA, UK 
- City Hospitals NHS Sunderland Foundation Trust, Neurology Department, 
Sunderland, SR4 7TP, UK 
- Hull and East Yorkshire Hospitals NHS Trust, Hull Royal Infirmary, Anlaby Rd, Hull 
HU3 2JZ 
- Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, 
Newcastle, NE1 4LP, UK 
The study will take place in an out-patient clinic room setting with support and oversight 
from the treating neurologist, nursing staff and research staff. Where appropriate, research 
delivery staff will be delegated to provide support with data collection and processing.  
Table 2: Anticipated timeline for PARAGON trial 
Month Setup Recruitment Analysis Finalise  
Jun-18 Submission for 
ethics/HRA 
approval 
   
Jun-18 NIHR portfolio 
adoption 
   
Aug-18 Ethics/HRA and 
Trust approval 
   
Sep-18  Start recruitment   
Jun-19  Finish recruitment   
Sep-19 
 
  Follow-up 
complete; 
Analyse data. 
manuscript & 
report writing 
 
 !""*!"&!""!"&(&'(&!!"
Participants will be recruited from neurology clinics and all eligible patients will be invited to 
take part until the required numbers have been achieved. Identification will be by the 
neurology clinical team, supported by the research staff. A screening form will be completed 
for potentially eligible patients to confirm that they indeed meet the trial criteria.  
To summarise, the neurologist team will: 
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- Identify potentially eligible patients and ask verbal consent for them being 
approached about the study by a member of the R&D team 
- Complete the incl/excl criteria part of the screening form (if a patient has given 
verbal consent to being approached by the research team then they can complete the 
screening form) 
 
 (&!&"! &!
Those eligible will be approached and provided with an information pack and consent form. 
If a patient wishes to participate, the consent form will be signed to indicate that informed 
consent has been given. Patients will be given ample time to consider taking part, more than 
24 hours if they wish. However, if the patient is comfortable with the study and fully 
understands what it entails then they are allowed to provide written informed consent 
within 24 hours.  
The study will be first mentioned at a neurology out-patient clinic visit.  The direct 
healthcare professional will first approach a patient about the study, and after verbal 
consent by the patient the healthcare professional themselves or a member of the research 
team can go through the informed consent process.  
As mentioned, patients are allowed to consent to taking part when first approached as long 
as the study has been discussed with the patient and they have been given time to read the 
patient information leaflet and had an opportunity to ask any questions that they may have. 
Participants will receive no incentives (apart from free use of the Curelator app) and consent 
will be regarded as a process and not a one-off event. Participants are free to withdraw 
from the study at any time without the need to give any reasons for withdrawal. Their 
standard of care will not be affected by either declining to participate in the study or 
withdrawing during participation. Data collected up to the date of withdrawal will be 
retained for analysis.  
Since GON block application may be dependent on the operator, block randomisation will 
be applied to ensure that one supine position patient will be recruited for each sitting 
position patient (stratified by migraine/other condition). 
 
 6%%7+*
Patients are in the study for a period of approximately 17 weeks – this includes 30 days 
before GON block and 90 days after the procedure. For Cluster Headache the baseline 
Curelator App recording period will be shorter at 14 days. Thereafter, the patient will be 
followed up as they would be in normal clinical practice. Study visits are aligned to 
hospital/clinic visits where possible and will take place remotely too where possible.  
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Baseline data is collected for a period of 30 days before the GON block procedure (14 days 
for Cluster Headache patients due to debilitating nature of their active phase and need for 
urgent GON block intervention), and Curelator data can commence up to 60 days prior to 
the planned GON block date (30 days for Cluster Headache patients). Participants are only 
randomised to one of the two intervention arms if they are compliant in daily use of the 
Curelator app (ie also when they do not have a headache, so that reliable data is collected). 
Unlike with a paper diary, there is no way of cheating and completing the diary at a later 
date. The Curelator dashboard will be used to monitor compliance; to ensure sufficient data 
is collated, participants must complete the diary 80% of days before the GON block 
appointment (equal to ≥ 24 out of 30 days minimum, or ≥ 12 out of 14 days for Cluster 
Headaches).  
For the 30 day and 90 day follow-up appointments, data can be collected in person to 
coincide with a clinic visit if applicable, over the phone, via e-mail or by mail (whichever is 
preferred by the patient – mail is by use of freepost, to avoid patients incurring any costs). 
The researcher will phone/e-mail/mail the participant at 30 days and 90 days post-GON 
block to ensure the patient reported outcome measures are collected, and also to check on 
any adverse event reporting. The follow-up procedures are the same for all types of 
headache conditions. 
 %"&((&(( &!%%7+*/"("!(
The treating neurologist will not conduct the follow-up questionnaires with the participants. 
A researcher or nurse who has not witnessed the actual GON block procedure and does not 
know the position that the participant was placed in post-GON block will conduct the follow-
ups. This only applies if the participants prefers to do the follow-up visits over the phone, 
rather than being sent the questionnaires via post or e-mail. 
 	! & &(&(
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- RELIEF score at 90 days post-GON block; the score will also be recorded at 30 days 
post-GON block 
 &)! & &(&(
 
- Headache-free period post-GON block in days 
- Average monthly headache days (before GON block and post-GON block) 
- Severity of headache (severe, moderate, mild, none)  
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- Headache characteristics  
 Including aura, photophobia 
- Average length of each headache episode in hours 
- Impact of headache disorder on quality of life 
 HIT-6, modified MIDAS, MSQ (latter for migraineurs only), see Appendix 4 
- Prophylactic and/or rescue medication use  
 Total cost of medicine use (before GON block and post-GON block), using 
British National Formulary as source for costs. 
- Adverse event reporting by participants 
All the outcome measures are summarised in Table 3. 
Table 3. Overview of measurements  
Item / timing -30 days to 
day 0 GON 
block* 
GON block 
to 10 min 
post-GON 
block 
30 days post-
GON block# 
90 days post-
GON block## 
Baseline demographics X    
Curelator diary X  X X 
VDS pain scale  X   
Headache characteristics 
questionnaire 
X  X X 
PROMs (HIT6, MIDAS, MSQ) X  X X 
Medication use X   X 
Headache-free days (patient recall)    X X 
RELIEF score   X X 
Curelator feedback questionnaire    X 
Safety recording   X X  
* Allowed to be up to 30 days early 
# Allowed to be up to 7 days early and 14 days late 
## Allowed to be up to 14 days early and 28 days late 
 
 
8 2

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Patients will be recruited from the adult (age 18+) population routinely seen by the 
evaluating clinical staff members.  The sample size calculations are based on results from a 
pilot study on patient positioning and GON block.  
The non-parametric Chi-squared test is used and 80% power and 5% significance is applied. 
A priori power calculations using GPower 3.1 software, result in the following sample size 
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summarized in Table 4. It also shows the number of responders and non-responders per 
patient position.  
The sample size calculation also takes into account a 30% patient attrition rate (withdrawal 
due to non-compliance with Curelator App before GON procedure and loss to follow-up), 
since this involves a study with multiple timepoints for data collection up to 90 days. 
Furthermore, in the pilot evaluation we observed a 10% drop-out rate and Curelator was 
not used in that study.   
In order to be able to analyse a pure subset of subjects with migraine, the samples size will 
take into account a ‘migraine only’ sample and a ‘other headache disorders’ sample – with 
each having a 1:1 randomised distribution of sitting and supine participants. Analysis will be 
performed on an intention-to-treat basis – ie lost participants post-GON block will be 
classed as a non-responder. 
Table 4:  Sample size calculation based on data from pilot study 
RELIEF score sitting Supine 
Non-responders (no relief, 
slight relief) 
18 (53%; 12 no relief, 6 
slight) 
17 (28%; 8 no relief, 9 slight) 
Responders (substantial 
relief, complete relief) 
16 (47%; 10 substantial, 6 
complete) 
44 (72%; 27 substantial, 17 
complete) 
total 34 61 
 
 Power beta of 80%, Alpha p-value of 0.05, Effect size 0.50 
 
Sample size required without any drop-out: 32 subjects.   
Sample size with 30% attrition rate included:  42 
 
Total of 42 migraine patients:   
 21 Patients in sitting position 
 21 Patient in supine position 
 
Total of 42 patients with other headache type:   
 21 Patients in sitting position  
 21 Patient in supine position 
 
Overall total: 84 
 
 
The CONSORT guidelines require a statement on the number of patients assessed for 
eligibility (Schulz, Altman & Moher 2010), see also Appendix 3. The number of patients 
screened but who did not meet the inclusion criteria or who declined to participate will be 
recorded, as will any patients who are lost to follow-up. 
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Following written consent, participants are allocated at random to the control or Coban 
intervention group, using a randomised sequence from the freeware randomisation 
programme, see https://www.randomizer.org/ .  Block randomisation, blocks of 6 patients 
to be allocated each time to a recruitment site, will be undertaken to ensure even 
distribution of cases from different clinicians into the two arms. Randomisation will also be 
stratified by cohort (migraine vs non-migraine cohorts). 
Sequential envelopes with each next randomisation allocation will be used to achieve 
concealment and these will be kept in the research department. The researcher or regular 
healthcare professional for the participant in question can e-mail (research@cumbria.nhs.uk  
or phone the R&D Dept (01228 602173) to determine which treatment the next participant 
has been allocated to. At this stage the Curelator dashboard will also be checked for 
baseline diary compliance. 
 %""$"%"!)"!&"
 %(""!&"
 
• Diagnosis fulfilling IHS criteria for primary headache disorder, which includes: 
For migraine cohort: 
- episodic or chronic migraine   
For non-migraine cohort 
- occipital neuralgia,  
- cluster headache,  
- trigeminal autonomic cephalgia (TAC) 
- non-specified or other primary headache disorder 
 
• Deemed eligible for GON block procedure as determined by treating neurology team 
• Aged 18 or older  
• Mental capacity to give written informed consent 
 9%(""!&"
• Under the age of 18 years 
• Unable to fully understand the consent process and provide informed consent due to 
either language barriers or mental capacity 
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• Any condition that precludes patients from receiving GON block, including: 
- Disorders associated with excessive bleeding, coagulation abnormalities or any other 
significant haematological condition (e.g. Factor V Leiden, haemophilia, 
thrombocytopaenia). 
- Known acute or previous base of skull fracture  
- Allergy or hypersensitivity to any active ingredients or excipients used for GON block 
• Patients who are participating in another interventional research study involving an 
investigational product related to their headache disorder. 
• The patient has concurrent (medical) conditions that in the opinion of the investigator 
may compromise patient safety or study objectives. 
• Subjects who have received greater occipital nerve blocks (both GON or Botox) in the 
last 6 months, or are still headache-free following an intervention. 
• For randomisation after baseline period: 
 Less than two headache episodes in baseline 30 day data collection period 
 Curelator App used < 25 days out of 30 day baseline diary period 
 %)7"!'7%($3&!(
Patients have the right to withdraw from the trial at any time and without giving any reason. 
If a patient withdraws from the trial, any and all information gathered prior to the 
withdrawal will be used in the analysis, but no further data collection will occur. If a patient 
does not attend a planned follow-up appointment then two more attempts will be made to 
contact the patient regarding the study. If still no contact can be made then the patient is 
deemed lost to follow-up and any collected study data will be retained. 
: 6
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There is no anticipated personal safety risk associated with taking part in this study. The 
only study intervention is the difference in patient position post-GON block. If the research 
team learns of important new information that might affect the patient’s desire to remain in 
the study, he or she will be told. Appropriate precautions are in place to ensure medical and 
personal information is kept safe through adhering to appropriate governance regulations. 
Any adverse events will be recorded, as outlined in sections below. Only adverse events that 
may occur in the 10 minute intervention period (ie sitting or supine following GON block) 
will be considered for safety reporting as part of the trial. As part of the trial, any other 
reported wider GON related issues will be recorded but are not deemed an AE. 
Participants cannot claim payments, reimbursement of expenses or any other benefits or 
incentives for taking part in this research. 
	 &!)&""!"(
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Adverse Event (AE) 
Any untoward medical occurrence in a patient or other clinical 
investigation participant taking part in a trial of a medical device, which 
does not necessarily have to have a causal relationship with the device 
under investigation.  
An AE can therefore be any unfavourable and unintended sign (including 
an abnormal laboratory finding), symptom or disease temporally 
associated with the use of the procedure, whether or not considered 
related to the procedure. 
Serious Adverse Event 
A serious adverse event is any untoward medical occurrence that: 
 results in death 
 is life-threatening 
 requires inpatient hospitalisation or prolongation of existing 
hospitalisation 
 results in persistent or significant disability/incapacity 
 consists of a congenital anomaly or birth defect. 
Other ‘important medical events’ may also be considered serious if they 
jeopardise the participant or require an intervention to prevent one of 
the above consequences. 
NOTE: The term "life-threatening" in the definition of "serious" refers to 
an event in which the participant was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have 
caused death if it were more severe. 

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All AEs need to be reported to the sponsor/host Trust R&D within ten working days of the 
investigator team becoming aware of them.  For this purpose an AE report form is 
completed by the researcher and/or Chief Investigator 
The relationship of each adverse event to the trial must be determined by the Chief 
Investigator, a medically qualified individual, according to the following definitions: 
• Related: The adverse event follows a reasonable temporal sequence from swabbing. 
It cannot reasonably be attributed to any other cause. 
• Not Related: The adverse event is probably produced by the participant’s clinical 
state or by other modes of therapy administered to the participant. 
• Severity grading: the Chief Investigator will also record if it concerns an AE or SAE. 
This is recorded on the aforementioned AE reporting form.  The forms are stored in the 
study site file. 
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Pseudo-anonymised copies of all adverse events forms will be shared with Curelator as soon 
as causality reporting has been performed and concluded. 
 
; 

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
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To determine the demographics and characteristics of the patients in the two arms the 
following data will be collated: 
• Age (yrs) 
• Gender 
• Height (kg), weight (cm), BMI 
• Headache disorder diagnosis 
• Typical location of headache pain 
• Chronicity of headache disorder 
• Use of prophylactic and/or rescue medication 
Any differences in distribution will be established with Chi-squared test or Mann-Whitney U-
test/t-test (depending on distribution of data) as indicated.  

 " )! &(!!"(!"(
To compare outcomes between the two groups (treatment response for sitting vs supine 
position post-GON at 90 days), Chi-squared test will be applied.  
 

 &)! &(!!"(!"(
The average baseline demographics for participants in each group will be compared to 
ascertain that randomisation has indeed led to comparable distribution of participants: 
Sex, age, height, weight, BMI, use of prophylactic and or rescue medication, type of 
headache disorder, chronicity of headache disorder, headache severity score, headache 
frequency score, average length of headache episodes, number of headache days, type of 
headache disorder (chronic vs episodic for migraine cohort and different headache 
disorders for non-migraine cohort).  
To compare outcomes between the two groups (treatment response for sitting vs supine 
position post-GON at 30 days), Chi-squared test will be applied. 
To compare headache-free outcomes between the two groups (headache-free days for 
sitting vs supine position post-GON), Mann-Whitney U-test will be applied. Although it will 
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likely apply, skewness in the distribution of data will first be assessed with the Shapiro Wilk 
test.  This analysis will be done for: the migraine cohort, non-migraine cohort, and cohorts 
combined.  
For the PROMs, Mann-Whiteney U-test will be applied. 
Cox proportional hazards regression analysis will be conducted to investigate the role of 
post-GON patient position and other covariates (as mentioned above) in post-GON 
severity/frequency/length of headaches, headache-free days and on the RELIEF score. 
Any impact of having undergone previous GON block on headache frequency, duration, 
symptoms and severity will be analysed too through regression analysis. 
 
< 
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Data arising from this study is confidential. Identifiable information can only be accessed by 
delegated members of the study team. Anyone in the research team who does not have a 
substantive contract with Cumbria Partnership NHS Trusts or one of the recruiting NHS 
Trusts will need to apply for a letter of access via the NIHR research passport scheme, 
should they require access to identifiable study data.  
Patient identifiable data will only be used within each respective Trust and by the core 
research team. All identifiable data is stored on password protected NHS computer systems. 
Anonymised data will be shared and stored using security-enabled systems such as 
password-protection and encryption of e-mails and files (including the use of nhs.net for 
correspondence via e-mail). The requirements of the Data Protection Act and NHS Code of 
Confidentiality will be followed at all times. All researchers will be fully trained in NHS 
Confidentiality and GCP.  Participants’ GP practices will be informed that they are taking 
part in the study.  
All paper data will be held in secure locked environments in the office of the Research & 
Development and Neurology department of Cumbria Partnership. Data released (e.g. by 
publication) will contain no information that could lead to the identification of an individual 
participant. Similar arrangements are to be made by any other participating recruitment 
site. Upon completion of the study the site files will be archived for a period of 15 years in 
line with local archiving policy and procedures. Direct access to data only will be granted to 
authorised representatives from the sponsor / host institution and the regulatory 
authorities to permit trial-related monitoring, audits and inspections. 
This investigator-initiated trial will be monitored in terms of conduct of the study by the in-
house research team, led by the Chief Investigator, who will convene on a monthly basis in 
person or via phone/e-mail. A formal trial steering committee will not be convened for this 
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trial – however, when data is available for 50% of the sample an interim analysis will take 
place to assess if there are any points of concern to consider. The study can be audited by 
the in-house R&D department as part of their rolling audit programme of sponsored and 
hosted research studies. As part of the research grant agreement, anonymised study data 
will be shared with Curelator Inc for review and for potential publication purposes. No 
identifiable data, will be contained in any of this data. However, as part of signing up to the 
Curelator App, the participants’ e-mail address will be shared with Curelator. They will not 
pass this information on to third parties. 
= #	-	6
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This study will be conducted in compliance with the protocol approved by the Health 
Research Authority, National Research Ethics Service, and local Trust R&D Approval, and 
according to Good Clinical Practice standards including the Declaration of Helsinki (1964, 
Amended Oct 2013). No deviation from the protocol will be implemented without the prior 
review and approval of the aforementioned review bodies, except where it may be 
necessary to eliminate an immediate hazard to a research subject. In such case, the 
deviation will be reported according to policies and procedures. 
 *(.& "!)
Cumbria Partnership NHS Trust is the sponsor of this study and therefore NHS indemnity 
applies for design, conduct and management of the study. Curelator Inc has provided a 
grant for this study by means of provision of the Curelator App free of charge for each 
participant (for the duration of the trial) and a research grant worth £1,000. 
Patients will not be given financial incentives for taking part in the study. Travel expenses 
are not offered in this study since patients are not seen in clinic more frequently than they 
would normally attend as part of their normal care pathway – Patient visit 3 at 30 days post-
GON block is a remote visit where patients will complete questionnaires from their own 
home. Participants will be given access to the Curelator app free of charge. 
 
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The study will be registered on ISRCTN or Clinical Trials Gov website, in line with CONSORT 
guidelines on good practice in clinical research (see Appendix 2). 
The results of this study are planned to be disseminated through:  
- Peer-reviewed manuscript in scientific journal  
- Presentation and/or poster at a scientific conference  
- Internal report to the funder of the trial, Curelator 
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As stated in the PIL and ICF, anonymised study data will be shared with Curelator as part of 
the research grant agreement. 
A summary of the main findings can be supplied to participants on request and this will be 
stated in the informed consent form. 
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Screening 
Patient identified by clinical staff member  
Verbal consent requested to explain study 
Screening form completed 
Patients are randomised  
Visit 2: GON block visit 
Between -60 to -0 
days: Consent 
process, baseline 
measures 
-60 to 0 days: start 
Curelator app 
Between -70 to -30 
days: screening and 
first approach  
0 days:  GON block 
Patient is allocated to SITTING group . Patient 
stays seated (vertical) for 10 min after GON block 
procedure 
Stratification by headache disorder (migraine vs 
non-migraine) 
Continue daily use of the Curelator App until day 90  
Visit 3 (30 days) and 4 (90 days): follow-up visits 
Patient-reported outcome measures: 
- RELIEF score (Complete, Substantial, Slight, None, Worsened scale) 
- Impression score for headache characteristics (severity, frequency, length) 
- Change in headache severity (using Severe-Moderate-Mild scale) 
- Headache-free days (patient reported) 
- Current prophylactic and/or rescue medication (day 90 only) 
- Other PROMS: HIT-6, modified MIDAS, MSQ (latter for migraine cohort only) 
[Collation of Curelator-derived data on headache-free  days, headache characteristics] 
Safety data – recording of any adverse events experienced by participants 
+ 30 days (+ 14/- 7 
days) 
& 
+ 90 days (+ 28/- 14 
days) 
Patient ineligible 
Patient declines to participate 
Visit 1: informed consent & baseline 
Patients have sufficient time to consider the study and ask questions; Consent is 
obtained, and recording of baseline measures and demographics.  
Commence daily use of the Curelator App [30 days baseline data – can be 
completed at any stage within -60 to 0 days window] 
Patient is allocated to SUPINE group. Patient lies 
down (horizontal) for 10 min directly after GON 
block procedure 
Stratification by headache disorder (migraine vs 
non-migraine) 
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Screening 
Patient identified by clinical staff member  
Verbal consent requested to explain study 
Screening form completed 
Patients are randomised  
Visit 2: GON block visit 
Between -30 to -0 
days: Consent 
process, baseline 
measures 
-30 to 0 days: start 
Curelator app 
Between -30 to -14 
days: screening and 
first approach  
0 days:  GON block 
Patient is allocated to SITTING group . Patient 
stays seated (vertical) for 10 min after GON block 
procedure 
Stratification by headache disorder (migraine vs 
non-migraine) 
Continue daily use of the Curelator App until day 90  
Visit 3 (30 days) and 4 (90 days): follow-up visits 
Patient-reported outcome measures: 
- RELIEF score (Complete, Substantial, Slight, None, Worsened scale) 
- Impression score for headache characteristics (severity, frequency, length) 
- Change in headache severity (using Severe-Moderate-Mild scale) 
- Headache-free days (patient reported) 
- Current prophylactic and/or rescue medication (day 90 only) 
- Other PROMS: HIT-6, modified MIDAS, MSQ (latter for migraine cohort only) 
[Collation of Curelator-derived data on headache-free  days, headache characteristics] 
Safety data – recording of any adverse events experienced by participants 
+ 30 days (+ 14/- 7 
days) 
& 
+ 90 days (+ 28/- 14 
days) 
Patient ineligible 
Patient declines to participate 
Visit 1: informed consent & baseline 
Patients have sufficient time to consider the study and ask questions; Consent is 
obtained, and recording of baseline measures and demographics.  
Commence daily use of the Curelator App [14 days baseline data – can be 
completed at any stage within -30 to 0 days window] 
Patient is allocated to SUPINE group. Patient lies 
down (horizontal) for 10 min directly after GON 
block procedure 
Stratification by headache disorder (migraine vs 
non-migraine) 
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Assessed for eligibility (n=  ) 
Excluded  (n=   ) 
♦   Not meeting inclusion criteria (n=  ) 
♦   Declined to participate (n=  ) 
♦   Other reasons (n=  ) 
Analysed  (n=  ) 
♦ Excluded from analysis (give reasons) (n=  ) 
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
♦ Received allocated intervention (n=  ) 
♦ Did not receive allocated intervention (give 
reasons) (n=  ) 
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
♦ Received allocated intervention (n=  ) 
♦ Did not receive allocated intervention (give 
reasons) (n=  ) 
Analysed  (n=  ) 
♦ Excluded from analysis (give reasons) (n=  ) 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=  ) 
Enrollment 
Screening Pre-enrollment screening  
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- Visual Display Pain scale 
- RELIEF scale (headache pain relief scale) 
- HIT-6 
- Modified MIDAS 
- MSQ (for migraine cohort only) 
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Visual Descriptor Pain score 
To be measured 10 minutes after the GON block procedure 
 
How painful was GON block procedure: 
 
Please put a vertical line on the numbered bar above. 
We kindly ask you consider the procedure as a whole and to summarise the discomfort/pain with 
one number. 

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RELIEF scale – headache pain relief scale. 
Since the GON block procedure, what has generally been the degree of headache pain relief you 
have experienced?  
 
 
Tick one box 
please 
Description 
 Pain has worsened  
 No relief 
 Slight relief 
 Substantial relief 
 Complete pain  relief 
 
  
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 38  
 
 
  
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 39  
 
  
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 40  
 
 
 
 
 
 
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 41  
 
 
 
 
 
 
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 42  
 
 
 
 
 
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 43  
 
 
 
 
 
 
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 44  
 
 
 
 
 
 
Confidential – This document and the information contained herein may not be reproduced, used or disclosed 
without written permission from Cumbria Partnership NHS Foundation Trust  Page | 45  
 
 
 
 
 
